Amikacin inhalation - PlumeStars

Drug Profile

Amikacin inhalation - PlumeStars

Latest Information Update: 26 Aug 2016

Price : $50

At a glance

  • Originator PlumeStars
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections

Most Recent Events

  • 26 Aug 2016 Chemical structure information added
  • 10 Aug 2016 Investigation in Cystic fibrosis-associated respiratory tract infections in Italy (Inhalation)
  • 10 Aug 2016 Investigation in Pseudomonal infections in Italy (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top